WO2019209208A3 - Compositions pharmaceutiques d'ivabradine à libération contrôlée - Google Patents

Compositions pharmaceutiques d'ivabradine à libération contrôlée Download PDF

Info

Publication number
WO2019209208A3
WO2019209208A3 PCT/TR2018/050818 TR2018050818W WO2019209208A3 WO 2019209208 A3 WO2019209208 A3 WO 2019209208A3 TR 2018050818 W TR2018050818 W TR 2018050818W WO 2019209208 A3 WO2019209208 A3 WO 2019209208A3
Authority
WO
WIPO (PCT)
Prior art keywords
controlled
ivabradine
pharmaceutical compositions
release pharmaceutical
release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/TR2018/050818
Other languages
English (en)
Other versions
WO2019209208A2 (fr
Inventor
Ali TÜRKYILMAZ
Arzu Palantöken
Dicle Güner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanovel Ilac Sanayi ve Ticaret AS
Original Assignee
Sanovel Ilac Sanayi ve Ticaret AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanovel Ilac Sanayi ve Ticaret AS filed Critical Sanovel Ilac Sanayi ve Ticaret AS
Publication of WO2019209208A2 publication Critical patent/WO2019209208A2/fr
Publication of WO2019209208A3 publication Critical patent/WO2019209208A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des compositions pharmaceutiques à libération contrôlée comprenant de l'ivabradine ou un sel, un solvate ou un polymorphe pharmaceutiquement acceptable de ce composé et au moins un agent à libération contrôlée.
PCT/TR2018/050818 2017-12-18 2018-12-17 Compositions pharmaceutiques d'ivabradine à libération contrôlée Ceased WO2019209208A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2017/20672 2017-12-18
TR2017/20672A TR201720672A2 (tr) 2017-12-18 2017-12-18 İvabradi̇ni̇n kontrollü salimli farmasöti̇k kompozi̇syonlari

Publications (2)

Publication Number Publication Date
WO2019209208A2 WO2019209208A2 (fr) 2019-10-31
WO2019209208A3 true WO2019209208A3 (fr) 2020-01-16

Family

ID=67900851

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2018/050818 Ceased WO2019209208A2 (fr) 2017-12-18 2018-12-17 Compositions pharmaceutiques d'ivabradine à libération contrôlée

Country Status (2)

Country Link
TR (1) TR201720672A2 (fr)
WO (1) WO2019209208A2 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010128525A2 (fr) * 2009-05-04 2010-11-11 Dinesh Shantilal Patel Préparation d'ivabradine dans le traitement des maladies cardiovasculaires
WO2011157720A2 (fr) * 2010-06-14 2011-12-22 Ratiopharm Gmbh Composition pharmaceutique contenant de l'ivabradine à libération modifiée
EP2740478A1 (fr) * 2011-08-05 2014-06-11 Jiangsu Hengrui Medicine Co., Ltd. Préparation à libération entretenue d'ivabradine ou de sels pharmaceutiquement acceptables de celle-ci

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010128525A2 (fr) * 2009-05-04 2010-11-11 Dinesh Shantilal Patel Préparation d'ivabradine dans le traitement des maladies cardiovasculaires
WO2011157720A2 (fr) * 2010-06-14 2011-12-22 Ratiopharm Gmbh Composition pharmaceutique contenant de l'ivabradine à libération modifiée
EP2740478A1 (fr) * 2011-08-05 2014-06-11 Jiangsu Hengrui Medicine Co., Ltd. Préparation à libération entretenue d'ivabradine ou de sels pharmaceutiquement acceptables de celle-ci

Also Published As

Publication number Publication date
TR201720672A2 (tr) 2019-07-22
WO2019209208A2 (fr) 2019-10-31

Similar Documents

Publication Publication Date Title
MY197700A (en) Compounds useful for inhibiting cdk7
SA520411524B1 (ar) مركبات تنشيط القسيم العضلي ثنائي الأميد واستخداماتها
AU2015336400A8 (en) Novel Aminoalkyl benzothiazepine Derivatives And Uses Thereof
WO2016205738A3 (fr) Systèmes d'administration pour la libération contrôlée de médicaments
PH12016502246A1 (en) Carboxamide derivatives
MX2020012989A (es) Agente terapeutico para la fibrosis.
MX2018014813A (es) Composiciones antibacterianas.
TN2016000491A1 (en) Carboxamide derivatives.
ZA201907588B (en) Potent hiv inhibiting lipopeptide, derivative thereof, pharmaceutical composition thereof and use thereof
WO2016006974A3 (fr) Nouveaux dérivés triazolopyrimidinone ou triazolopyridinone et leur utilisation
WO2016006975A3 (fr) Nouveaux dérivés imidazotriazinone ou imidazopyrazinone et leur utilisation
EP4342542A3 (fr) Combinaison d'inhibiteurs de régorafénib et de pd-1/pd-l1(2) pour le traitement du cancer
PH12018500980A1 (en) Amorphous solifenacin-containing solid preparation for oral use and preparation method therefor
TR201715231A2 (tr) Dapokseti̇n ve fosfodi̇esteraz ti̇p-5 i̇nhi̇bi̇törü i̇çeren farmasöti̇k kombi̇nasyon
WO2019190427A3 (fr) Combinaison à libération immédiate comprenant du raloxifène et au moins un agent anti-psychotique
TR201714882A2 (tr) Luli̇konazolün topi̇kal farmasöti̇k kompozi̇syonlari
WO2019203747A3 (fr) Combinaison pharmaceutique comprenant du raloxifène et au moins un agent antipsychotique
WO2019221684A3 (fr) Formulation de comprimé bicouche de fésotérodine
MX2016013428A (es) Composiciones farmaceuticas que comprenden agentes antibacterianos.
EP3604291A4 (fr) Composé ou sel de celui-ci, agent antiviral et composition pharmaceutique
TR201720672A2 (tr) İvabradi̇ni̇n kontrollü salimli farmasöti̇k kompozi̇syonlari
TR201720510A2 (tr) Orally disintegrating tablet formulations of ivabradine
MX2022005932A (es) Composiciones farmaceuticas de ivabradina de liberacion prolongada.
PH12019501689A1 (en) Composition comprising immediate release and extended release capecitabine
WO2019151967A3 (fr) Formulations de comprimés dispersibles dans l'eau comprenant du déférasirox

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18916469

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18916469

Country of ref document: EP

Kind code of ref document: A2